Département de Pharmacochimie Moléculaire, UMR 5063 & ICMG FR-2607, CNRS/Université Joseph Fourier, BP 53, 38041 Grenoble Cedex 9, France.
Mol Divers. 2012 Nov;16(4):659-67. doi: 10.1007/s11030-012-9397-7. Epub 2012 Sep 19.
A small library of heterocycle-fused quinazolin-4-ones was prepared and evaluated as kinase inhibitors. The key step of the two-step process involves the environmental friendly thermolysis of N-ethoxycarbonyl-N'-(hetero) arylguanidines at 130 °C in water. The cyclization is fully regioselective. The most active molecules, 7-(2-hydroxyethylamino)- and 7-(3-hydroxypropylamino)-pyrazolo[4,3-f]quinazolin-9-ones, inhibit DYRK1A and CLK1 at submicromolar concentrations, indicating the potential interest of this new heterocycle in drug design.
合成了一个包含杂环稠合喹唑啉-4-酮的小文库,并将其作为激酶抑制剂进行了评估。两步法的关键步骤包括在 130°C 下于水中进行环保的 N-乙氧羰基-N'-(杂环)芳基胍的热解。环化反应具有完全的区域选择性。最具活性的分子 7-(2-羟乙基氨基)-和 7-(3-羟丙基氨基)-吡唑并[4,3-f]喹唑啉-9-酮以亚微摩尔浓度抑制 DYRK1A 和 CLK1,表明该新杂环在药物设计中的潜在价值。